RecruitingNCT06147466

Time Spent In Target Glucose Range in Women With T2D Diabetes in Pregnancy

Time Spent In the Target Glucose Range and MatErnaL and Neonatal Effects in Women With tYpe 2 Diabetes in Pregnancy (TIMELY)


Sponsor

Mount Sinai Hospital, Canada

Enrollment

50 participants

Start Date

Mar 1, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Prospective cohort study to determine to what extent women with type 2 diabetes are achieving the time in the target range outlined for women with type 1 diabetes (70-140 mg/dl or 3.5-7.8 mmol/l), overall and by trimester, by standard CGM measures and functional data analysis


Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tracks how much time pregnant women with Type 2 diabetes spend with their blood sugar levels in the ideal target range, using continuous glucose monitoring (CGM) devices worn on the body, to improve diabetes management during pregnancy. **You may be eligible if...** - You are a pregnant woman diagnosed with Type 2 diabetes before pregnancy or before 20 weeks of pregnancy - You are 14 weeks pregnant or less - You are 18 years or older - You have access to email and are willing to use the study devices **You may NOT be eligible if...** - You have Type 1 diabetes or gestational diabetes - You are taking medications that interfere with blood sugar (such as high-dose steroids) - You are allergic to insulin - You have serious kidney disease (eGFR below 30), severe nerve problems, or uncontrolled gastroparesis - You have severe vision or hearing impairment that affects your ability to use the study devices - You cannot communicate effectively in English Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEDexcom Continuous Glucose Monitoring

A continuous glucose monitor (CGM) is a wearable device that tracks blood glucose (sugar) every few minutes, throughout the day and night. The readings are relayed in real time to a device which can be read by the patient, caregiver or health-care provider, even remotely


Locations(1)

Mount Sinai Hospital

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06147466


Related Trials